CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biodesix Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biodesix Inc
919 West Dillon Road
Phone: (302) 658-7581p:302 658-7581 LOUISVILLE, CO  80027  United States Ticker: BDSXBDSX
Business Summary
Biodesix, Inc. is a diagnostic solutions company. It offers two tests (Nodify Lung tests) that assess the risk of cancer in lung nodules and three tests (IQLung tests) that provide treatment guidance after a lung cancer diagnosis. Nodify CDT and Nodify XL2 tests, marketed as Nodify Lung Nodule Risk Assessment, assess the lung nodule's risk of lung cancer to help identify the appropriate treatment pathway. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from surveillance imaging. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests, marketed as part of its IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient’s immune system to help guide treatment decisions.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
8071 Medical laboratories
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board JohnPatience 77 9/1/2020 6/1/2008
President, Chief Executive Officer, Director ScottHutton 53 1/1/2020 3/1/2018
Chief Financial Officer, Treasurer, Secretary Robin H.Cowie 45 1/1/2020
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Integrated Diagnostics, Inc. 1441 N. 34th Street Seattle WA United States

Business Names
Business Name
BDSX
Integrated Diagnostics, Inc.

General Information
Number of Employees: 334 (As of 12/31/2025)
Outstanding Shares: 10,107,219 (As of 3/23/2026)
Shareholders: 228
Stock Exchange: NASD
Federal Tax Id: 203986492
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 11, 2026